Xcout Intel
F2G competitors & alternatives
The 12 closest competitors and alternatives to F2G among biopharmaceutical companies — ranked by similarity to what F2G actually does, not by market-cap band.
Subscribe to see F2G’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About F2G
F2G is a biotechnology research company headquartered in the UK with subsidiaries in the US and Austria. The company specializes in developing novel therapeutics and antifungal treatments for rare fungal infections.
F2G at a glance
F2G is a biopharmaceutical company headquartered in United Kingdom. It has raised at least $220.8M across the 3 funding rounds on record. Its most recent funding round raised $100M in September 2024. Xcout tracks 20 named people at F2G, including Francesco Maria Lavino (Chief Executive Officer).
F2G leadership
- Francesco Maria LavinoChief Executive Officer
- Mike Birch, PhDChief Operating Officer
- Ralf SchmidChief Financial Officer
- Janelle R. Anderson, PhDChief Business Officer
- John H. Rex, MDChief Medical Officer
- Mark BaglinChief Commercial Officer
14 more named people on record for F2G, with roles, board committees and tenure — see the full roster →
F2G funding rounds
At least $220.8M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $100M | 10 named | |
| — | $60.8M | 11 named | |
| — | $60M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 F2G competitors
Ranked by semantic similarity — how close each company is to F2G by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biopharma
Amplyx Pharmaceuticals, Inc. was a San Diego-based clinical-stage biotechnology company developing treatments for serious and potentially life-threatening fungal infections. Its lead investigational drug, fosmanogepix, was acquired by Pfizer when Pfizer acquired Amplyx in 2021 and is being developed for patients with invasive fungal diseases.
Biopharmaceuticals
Cidara Therapeutics, Inc. is a biotechnology company focused on developing late-phase antiviral and immunotherapy agents, with operations based in San Diego, California and Rahway, New Jersey.
Drug Discovery
Pulmocide is a UK drug-discovery and development company focused on inhaled treatments for serious fungal lung infections. Its lead candidate, opelconazole (PC945), is an inhaled antifungal being developed for pulmonary aspergillosis and related respiratory fungal diseases, serving patients with difficult-to-treat pulmonary infections.
Biopharmaceuticals
CAGE Bio is a clinical-stage biotechnology company that develops localized therapies for dermatology, inflammation, and immunology. The company utilizes a proprietary deep eutectic ionic liquid platform to enable the skin penetration of small and large molecules, providing topical treatments designed to avoid the side effects of systemic drug exposure.
Biopharmaceuticals
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
Biopharmaceuticals
Achaogen Inc was a biopharmaceutical company headquartered in South San Francisco, California. The company focused on discovering, developing, and commercializing novel antibacterial treatments.
Biopharmaceuticals
Dermira, Inc. is a biotechnology company focused on medical dermatology, with its main headquarters located in Menlo Park, California, United States.
Drug Discovery
FundaMental Pharma is a biopharmaceutical spin-off established from Heidelberg University and headquartered in Heidelberg, Germany. Its research focuses on developing novel therapeutic approaches and treatments for neurological disorders.
Drug Discovery
Kupando is a pioneering Berlin-based biopharmaceutical and biotech company headquartered in Schönefeld, Germany. The company is focused on the research and clinical development of innovative treatments to fight cancer and infectious diseases.
Drug Discovery
Ochre Bio is a biotechnology company developing precision medicines for chronic liver diseases. It uses data from human donor livers, computational biology, and experimental models to identify and validate therapeutic targets for pharmaceutical and biotechnology development.
Drug Discovery
Automera is an early-stage biotechnology research company headquartered in Singapore. The company focuses on the development of novel therapeutics through autophagy-based targeted protein degradation.
Drug Discovery
Baseimmune is a biotechnology research company headquartered in London, United Kingdom, pioneering active immunotherapies. The company combines cutting-edge computational design with advanced protein engineering to develop next-generation vaccines.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of F2G and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for F2Gand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →